BioNTech is a biotechnology company based in Mainz, Germany, that focuses on the development of immunotherapies for cancer and infectious diseases. Founded in 2008, the company is known for pioneering the use of messenger RNA (mRNA) technology to create vaccines and therapeutics. It gained global recognition for its collaboration with Pfizer, leading to the rapid development of the BNT162b2 vaccine, which was one of the first COVID-19 vaccines authorized for emergency use during the pandemic. BioNTech’s innovative approach leverages the body’s immune system to target and fight diseases, and the company’s research extends beyond vaccines to include personalized cancer therapies and other treatment modalities.
BioNTech faces a transition as COVID-19 vaccine revenue declines, focusing on mRNA-based cancer therapies. The company reports a significant financial downturn: fourth-quarter 2024 EPS fell to 1.08 euros, and full-year…